{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:56:04Z","timestamp":1780725364328,"version":"3.54.1"},"reference-count":127,"publisher":"American Association for Cancer Research (AACR)","issue":"20","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer (DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), is the most frequent subtype of thyroid cancer; more rare subtypes are medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC). The incidence of DTC has increased rapidly in recent years due to the more frequent use of imaging methods such as ultrasound of the neck and fine-needle aspiration (FNA) of thyroid nodules. After total thyroidectomy and radioiodine treatment, DTC remains an indolent and curable disease in most patients, whereas the cure rate in MTC is lower and depends on early diagnosis. Most ATCs are incurable. In recent years, there has been great progress in identifying genetic changes in thyroid cancer, and genetic testing of FNA samples or blood samples provides useful information for clinical decision making. Tumor staging, either postoperatively or by imaging, and measuring the tumor markers thyroglobulin for DTC and calcitonin for MTC, allow for dynamic risk-adapted stratification for follow-up procedures. In advanced metastatic thyroid cancer, molecular targeted therapy using tyrosine kinase receptor inhibitors, including sorafenib, lenvantinib, vandetanib, and cabozantinib, helps control tumor progression and prolongs progression-free survival. Using a dynamic risk-stratified approach to manage thyroid cancer, the outcomes for most thyroid cancer patients are excellent compared with those for other cancers. The major challenge in the future is to identify high-risk patients and to treat and monitor them appropriately. Clin Cancer Res; 22(20); 5012\u201321. \u00a92016 AACR.<\/jats:p><jats:p>See all articles in this CCR Focus section, \u201cEndocrine Cancers: Revising Paradigms.\u201d<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-16-0484","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T04:39:31Z","timestamp":1476419971000},"page":"5012-5021","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Thyroid Cancer: Risk-Stratified Management and Individualized Therapy"],"prefix":"10.1158","volume":"22","author":[{"given":"Friedhelm","family":"Raue","sequence":"first","affiliation":[{"name":"Molecular Laboratory, Endocrine Practice, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Frank-Raue","sequence":"additional","affiliation":[{"name":"Molecular Laboratory, Endocrine Practice, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"key":"2022061102561700100_bib1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrendo.2012.257","article-title":"Increasing incidence of thyroid cancer: controversies explored","volume":"9","author":"Ito","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"2022061102561700100_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1089\/thy.2004.14.1056","article-title":"Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee","volume":"14","author":"Leenhardt","year":"2004","journal-title":"Thyroid"},{"key":"2022061102561700100_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/105072502753522374","article-title":"Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982\u20131997)","volume":"12","author":"Burgess","year":"2002","journal-title":"Thyroid"},{"key":"2022061102561700100_bib4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMp1409841","article-title":"Korea's thyroid-cancer \"epidemic\"\u2013screening and overdiagnosis","volume":"371","author":"Ahn","year":"2014","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2022061102561700100_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","article-title":"Current thyroid cancer trends in the United States","volume":"140","author":"Davies","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2022061102561700100_bib7","volume-title":"SEER cancer statistics review, 1975\u20132013 [monograph on the Internet]","author":"Howlader","year":"2016"},{"key":"2022061102561700100_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(12)62205-3","article-title":"Controversies in primary treatment of low-risk papillary thyroid cancer","volume":"381","author":"McLeod","year":"2013","journal-title":"Lancet"},{"key":"2022061102561700100_bib9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1089\/thy.2014.0594","article-title":"The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: population-based study in Olmsted County, Minnesota during 1935 through 2012","volume":"25","author":"Brito","year":"2015","journal-title":"Thyroid"},{"key":"2022061102561700100_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1089\/thy.2013.0257","article-title":"The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds","volume":"24","author":"Udelsman","year":"2014","journal-title":"Thyroid"},{"key":"2022061102561700100_bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.2013.0045","article-title":"The increasing incidence of thyroid cancer: the influence of access to care","volume":"23","author":"Morris","year":"2013","journal-title":"Thyroid"},{"key":"2022061102561700100_bib12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.6004\/jnccn.2010.0093","article-title":"Thyroid carcinoma","volume":"8","author":"Tuttle","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"2022061102561700100_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3346\/jkms.2014.29.5.676","article-title":"Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy","volume":"29","author":"Lee","year":"2014","journal-title":"J Korean Med Sci"},{"key":"2022061102561700100_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrendo.2012.38","article-title":"Advances in the follow-up of differentiated or medullary thyroid cancer","volume":"8","author":"Elisei","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022061102561700100_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2022061102561700100_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12515","article-title":"Guidelines for the management of thyroid cancer","volume":"81","author":"Perros","year":"2014","journal-title":"Clin Endocrinol"},{"key":"2022061102561700100_bib17","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2022061102561700100_bib18","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s00268-014-2498-y","article-title":"Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma","volume":"38","author":"Takami","year":"2014","journal-title":"World J Surg"},{"key":"2022061102561700100_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1530\/eje.1.02158","article-title":"European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium","volume":"154","author":"Pacini","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"2022061102561700100_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00423-013-1057-6","article-title":"German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors","volume":"398","author":"Dralle","year":"2013","journal-title":"Langenbecks Arch Surg"},{"key":"2022061102561700100_bib22","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma [database on the Internet]","year":"2014"},{"key":"2022061102561700100_bib23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4158\/EP.16.3.468","article-title":"American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations","volume":"16","author":"Gharib","year":"2010","journal-title":"Endocr Pract"},{"key":"2022061102561700100_bib24","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1210\/jc.2015-3100","article-title":"The influence of patient age on thyroid nodule formation, multinodularity, and thyroid cancer risk","volume":"100","author":"Kwong","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib25","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1148\/radiol.11110206","article-title":"Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk","volume":"260","author":"Kwak","year":"2011","journal-title":"Radiology"},{"key":"2022061102561700100_bib26","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2006-0690","article-title":"Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography","volume":"91","author":"Frates","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1089\/thy.2014.0353","article-title":"Thyroid ultrasound features and risk of carcinoma: a systematic review and meta-analysis of observational studies","volume":"25","author":"Remonti","year":"2015","journal-title":"Thyroid"},{"key":"2022061102561700100_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1309\/AJCPXM9WIRQ8JZBJ","article-title":"The Bethesda System for reporting thyroid fine-needle aspiration specimens","volume":"134","author":"Crippa","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2022061102561700100_bib29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1309\/AJCPPHLWMI3JV4LA","article-title":"The Bethesda System for Reporting Thyroid Cytopathology","volume":"132","author":"Cibas","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"2022061102561700100_bib30","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1158\/1078-0432.CCR-12-1253","article-title":"New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers","volume":"19","author":"Nikiforov","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022061102561700100_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2022061102561700100_bib32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2022061102561700100_bib33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"2022061102561700100_bib34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1089\/thy.2012.0372","article-title":"Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2","volume":"23","author":"Carina","year":"2013","journal-title":"Thyroid"},{"key":"2022061102561700100_bib35","doi-asserted-by":"crossref","first-page":"E2031","DOI":"10.1210\/jc.2012-2092","article-title":"Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon","volume":"97","author":"Boichard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/thy.2012.0207","article-title":"Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series","volume":"23","author":"Ciampi","year":"2013","journal-title":"Thyroid"},{"key":"2022061102561700100_bib37","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib38","doi-asserted-by":"crossref","first-page":"e1005467","DOI":"10.1371\/journal.pgen.1005467","article-title":"Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer","volume":"11","author":"Ji","year":"2015","journal-title":"PLoS Genet"},{"key":"2022061102561700100_bib39","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.humpath.2014.03.010","article-title":"Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens","volume":"45","author":"Giordano","year":"2014","journal-title":"Hum Pathol"},{"key":"2022061102561700100_bib40","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1245\/s10434-012-2851-z","article-title":"Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases","volume":"20","author":"Zheng","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2022061102561700100_bib41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2265.2006.02605.x","article-title":"The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma","volume":"65","author":"Kim","year":"2006","journal-title":"Clin Endocrinol"},{"key":"2022061102561700100_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-15-0254","article-title":"BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma","volume":"173","author":"Bastos","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1530\/ERC-14-0531","article-title":"BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis","volume":"22","author":"Li","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"2022061102561700100_bib44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1089\/thy.2015.0488","article-title":"Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAFV600E mutation-prevalent population","volume":"26","author":"Lee","year":"2016","journal-title":"Thyroid"},{"key":"2022061102561700100_bib45","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/thy.2015.0305","article-title":"Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance\/follicular lesion of undetermined significance cytology","volume":"25","author":"Nikiforov","year":"2015","journal-title":"Thyroid"},{"key":"2022061102561700100_bib46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1203208","article-title":"Preoperative diagnosis of benign thyroid nodules with indeterminate cytology","volume":"367","author":"Alexander","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib47","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1245\/s10434-015-4486-3","article-title":"Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules","volume":"22","author":"Marti","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2022061102561700100_bib48","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/thy.2015.0505","article-title":"Clinical factors influencing the performance of gene expression classifier testing in indeterminate thyroid nodules","volume":"26","author":"Wu","year":"2016","journal-title":"Thyroid"},{"key":"2022061102561700100_bib49","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"key":"2022061102561700100_bib50","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/jc.2010-1082","article-title":"Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status","volume":"96","author":"Kim","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10434-004-1165-1","article-title":"Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer","volume":"12","author":"Haigh","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2022061102561700100_bib52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hed.21504","article-title":"Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer","volume":"33","author":"Barney","year":"2011","journal-title":"Head Neck"},{"key":"2022061102561700100_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/thy.2013.0367","article-title":"Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation","volume":"24","author":"Ito","year":"2014","journal-title":"Thyroid"},{"key":"2022061102561700100_bib54","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/thy.2015.0313","article-title":"Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery","volume":"26","author":"Oda","year":"2016","journal-title":"Thyroid"},{"key":"2022061102561700100_bib55","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12020-012-9729-5","article-title":"Radioiodine treatment of well-differentiated thyroid cancer","volume":"42","author":"Wartofsky","year":"2012","journal-title":"Endocrine"},{"key":"2022061102561700100_bib56","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","article-title":"Strategies of radioiodine ablation in patients with low-risk thyroid cancer","volume":"366","author":"Schlumberger","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib57","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1002\/cncr.26070","article-title":"Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy","volume":"117","author":"Iyer","year":"2011","journal-title":"Cancer"},{"key":"2022061102561700100_bib58","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib59","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0014-2964(79)90291-3","article-title":"A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group","volume":"15","author":"Byar","year":"1979","journal-title":"Eur J Cancer"},{"key":"2022061102561700100_bib60","first-page":"1088","article-title":"Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system","volume":"102","author":"Hay","year":"1987","journal-title":"Surgery"},{"key":"2022061102561700100_bib61","first-page":"947","article-title":"An expanded view of risk-group definition in differentiated thyroid carcinoma","volume":"104","author":"Cady","year":"1988","journal-title":"Surgery"},{"key":"2022061102561700100_bib62","first-page":"1036","article-title":"Intermediate-risk group for differentiated carcinoma of thyroid","volume":"116","author":"Shaha","year":"1994","journal-title":"Surgery"},{"key":"2022061102561700100_bib63","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ecl.2014.02.010","article-title":"Update on differentiated thyroid cancer staging","volume":"43","author":"Momesso","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2022061102561700100_bib64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1530\/EJE-11-0466","article-title":"Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients","volume":"165","author":"Castagna","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib65","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1089\/thy.2011.0232","article-title":"In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response","volume":"21","author":"Vaisman","year":"2011","journal-title":"Thyroid"},{"key":"2022061102561700100_bib66","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1089\/thy.2013.0011","article-title":"Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems","volume":"23","author":"Pitoia","year":"2013","journal-title":"Thyroid"},{"key":"2022061102561700100_bib67","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2010.0178","article-title":"Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"key":"2022061102561700100_bib68","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1089\/thy.2010.0355","article-title":"Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy","volume":"21","author":"Miyauchi","year":"2011","journal-title":"Thyroid"},{"key":"2022061102561700100_bib69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-319-22542-5_3","article-title":"Epidemiology and clinical presentation of medullary thyroid carcinoma","volume":"204","author":"Raue","year":"2015","journal-title":"Recent Results Cancer Res"},{"key":"2022061102561700100_bib70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jso.20269","article-title":"Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement","volume":"91","author":"Bugalho","year":"2005","journal-title":"J Surg Oncol"},{"key":"2022061102561700100_bib71","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF03344126","article-title":"Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study","volume":"29","author":"Papi","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"2022061102561700100_bib72","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hed.21228","article-title":"Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules","volume":"32","author":"Hasselgren","year":"2010","journal-title":"Head Neck"},{"key":"2022061102561700100_bib73","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1210\/jc.2013-4088","article-title":"Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety","volume":"99","author":"Mian","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib74","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1677\/ERC-09-0136","article-title":"Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer","volume":"16","author":"Machens","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"2022061102561700100_bib75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-319-22542-5_6","article-title":"Hereditary medullary thyroid cancer genotype-phenotype correlation","volume":"204","author":"Frank-Raue","year":"2015","journal-title":"Recent Results Cancer Res"},{"key":"2022061102561700100_bib76","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa012915","article-title":"Early malignant progression of hereditary medullary thyroid cancer","volume":"349","author":"Machens","year":"2003","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib77","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/eje.1.02216","article-title":"Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype","volume":"155","author":"Frank-Raue","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib78","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa043999","article-title":"Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A","volume":"353","author":"Skinner","year":"2005","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib79","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1530\/eje.0.1410468","article-title":"Early or prophylactic thyroidectomy in MEN 2\/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC)","volume":"141","author":"Niccoli-Sire","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib80","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/thy.2014.0277","article-title":"Response to initial therapy predicts clinical outcomes in medullary thyroid cancer","volume":"25","author":"Lindsey","year":"2015","journal-title":"Thyroid"},{"key":"2022061102561700100_bib81","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-319-22542-5_10","article-title":"Long-term follow-up in medullary thyroid carcinoma","volume":"204","author":"Raue","year":"2015","journal-title":"Recent Results Cancer Res"},{"key":"2022061102561700100_bib82","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2265.2001.01339.x","article-title":"Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma","volume":"55","author":"Franc","year":"2001","journal-title":"Clin Endocrinol"},{"key":"2022061102561700100_bib83","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0039-6060(03)00408-2","article-title":"Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients","volume":"134","author":"Yen","year":"2003","journal-title":"Surgery"},{"key":"2022061102561700100_bib84","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.bjc.6600930","article-title":"Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging","volume":"88","author":"Pellegriti","year":"2003","journal-title":"Br J Cancer"},{"key":"2022061102561700100_bib85","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/SLA.0b013e318268301d","article-title":"Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system","volume":"257","author":"Machens","year":"2013","journal-title":"Ann Surg"},{"key":"2022061102561700100_bib86","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1210\/jc.2009-2368","article-title":"Biomarker-based risk stratification for previously untreated medullary thyroid cancer","volume":"95","author":"Machens","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib87","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0039-6060(03)00424-0","article-title":"Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer","volume":"134","author":"Kouvaraki","year":"2003","journal-title":"Surgery"},{"key":"2022061102561700100_bib88","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"key":"2022061102561700100_bib89","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1210\/jc.2007-1211","article-title":"Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels","volume":"92","author":"Giraudet","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib90","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2967\/jnumed.107.047720","article-title":"18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation","volume":"49","author":"Koopmans","year":"2008","journal-title":"J Nucl Med"},{"key":"2022061102561700100_bib91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ejso.2007.08.005","article-title":"The role of 18F-FDG PET\/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study","volume":"34","author":"Rubello","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"2022061102561700100_bib92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2022061102561700100_bib93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-07-0667","article-title":"Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times","volume":"158","author":"Laure Giraudet","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib94","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib95","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1530\/ERC-15-0194","article-title":"Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review","volume":"23","author":"Albero","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2022061102561700100_bib96"},{"key":"2022061102561700100_bib97","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022061102561700100_bib98","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022061102561700100_bib99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2022061102561700100_bib100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib101","doi-asserted-by":"crossref","article-title":"Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline","author":"Schlumberger","DOI":"10.1200\/jco.2015.33.15_suppl.6012"},{"key":"2022061102561700100_bib102","article-title":"Effect of age and lenvatinib treatment on overall survival for patients with 131-I-refractory differentiated thyroid cancer in SELECT","author":"Brose"},{"key":"2022061102561700100_bib103","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMc1215697","article-title":"BRAF V600E inhibition in anaplastic thyroid cancer","volume":"368","author":"Rosove","year":"2013","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib104","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib105","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1530\/ERC-15-0555","article-title":"Treatment of advanced thyroid cancer with targeted therapies: ten years of experience","volume":"23","author":"Viola","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2022061102561700100_bib106","doi-asserted-by":"crossref","first-page":"R287","DOI":"10.1530\/ERC-16-0104","article-title":"New drugs for medullary thyroid cancer: new promises?","volume":"23","author":"Spitzweg","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2022061102561700100_bib107","first-page":"2787","article-title":"Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells","volume":"31","author":"Arao","year":"2011","journal-title":"Anticancer Res"},{"key":"2022061102561700100_bib108","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","article-title":"MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy","volume":"11","author":"Finke","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"2022061102561700100_bib109","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1530\/EJE-14-0788","article-title":"Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis","volume":"172","author":"Klein Hesselink","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib110","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1210\/jc.2013-2622","article-title":"Update: the status of clinical trials with kinase inhibitors in thyroid cancer","volume":"99","author":"Wells","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib111","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/cncr.28766","article-title":"Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic\/pharmacodynamic and quality-of-life assessments","volume":"120","author":"Locati","year":"2014","journal-title":"Cancer"},{"key":"2022061102561700100_bib112","doi-asserted-by":"crossref","first-page":"348124","DOI":"10.1155\/2015\/348124","article-title":"Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial","volume":"2015","author":"Schneider","year":"2015","journal-title":"Int J Endocrinol"},{"key":"2022061102561700100_bib113","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2007.0120","article-title":"A phase II study of gefitinib in patients with advanced thyroid cancer","volume":"18","author":"Pennell","year":"2008","journal-title":"Thyroid"},{"key":"2022061102561700100_bib114","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","article-title":"A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma","volume":"92","author":"de Groot","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/EJE-06-0695","article-title":"Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma","volume":"157","author":"Frank-Raue","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib116","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/thy.2010.0057","article-title":"A phase II study of imatinib in patients with advanced anaplastic thyroid cancer","volume":"20","author":"Ha","year":"2010","journal-title":"Thyroid"},{"key":"2022061102561700100_bib117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022061102561700100_bib118","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022061102561700100_bib119","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061102561700100_bib120","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022061102561700100_bib121","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer","volume":"97","author":"Bible","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022061102561700100_bib122","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"Hayes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061102561700100_bib123","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/EJE-12-0405","article-title":"Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial","volume":"167","author":"Schneider","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2022061102561700100_bib124","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061102561700100_bib125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","article-title":"Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid","volume":"23","author":"Savvides","year":"2013","journal-title":"Thyroid"},{"key":"2022061102561700100_bib126","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061102561700100_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","author":"Brose","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/22\/20\/5012\/2033311\/5012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/22\/20\/5012\/2033311\/5012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T22:53:58Z","timestamp":1718837638000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/22\/20\/5012\/124854\/Thyroid-Cancer-Risk-Stratified-Management-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":127,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2016,10,13]]},"published-print":{"date-parts":[[2016,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0484","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,13]]}}}